Tags

Type your tag names separated by a space and hit enter

A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
Hematol Oncol Stem Cell Ther 2012; 5(1):36-41HO

Abstract

BACKGROUND AND OBJECTIVES

Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin lymphoma with a favorable prognosis remains unclear. Therefore, we conducted this randomized trial, comparing two treatment groups consisting of a combination chemotherapy regimen of two different intensities followed by involved-field radiation therapy at two different dose levels.

DESIGN AND SETTING

Prospective, randomized, in patients referred to the Department Of Clinical Oncology And Nuclear Medicine.

PATIENTS AND METHODS

Ninety-eight patients with histologically proven early-stage Hodgkin lymphoma with a favorable prognosis were enrolled in this study between January 2008 and June 2010. They were randomly assigned in one of two treatment arms: arm I received four cycles of ABVD (adriamycin, belomycin, vinblastine, dacarbazine) followed by 30 Gy of involved-field radiation therapy; arm II received two cycles of ABVD followed by 20 Gy of involved-field radiation therapy.

RESULTS

During the follow-up period, the 2-year relapse-free survival rates were 96% and 95% in arm I and arm II, respectively (P=.8), while the 2-year overall survival rates were 98% and 95% in arm I and arm II, respectively (P=.16). acute toxicity affected 54% of patients treated with four cycles of ABVD, who had grade III or IV toxicity, as compared with 30% of those receiving two cycles (P<.02). The rates of acute toxicity (grade III or IV) were also higher among patients treated with 30 Gy of involved-field radiation therapy than among those receiving 20 Gy (16% vs. 2.5%, P<.03) .

CONCLUSION

In patients with early-stage Hodgkin lymphoma and a favorable prognosis, treatment with two cycles of aBVD followed by 20 Gy of involved-field radiation therapy was as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy.

Authors+Show Affiliations

Department Of Clinical Oncology And Nuclear Medicine, Mansoura University, Mansoura Egypt. rashahamdy22@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22446609

Citation

Hamed, R H., et al. "A Randomized Trial of Brief Treatment of Early- Stage Hodgkin Lymphoma: Is It Effective?" Hematology/oncology and Stem Cell Therapy, vol. 5, no. 1, 2012, pp. 36-41.
Hamed RH, Anter AH, Awad IA. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective? Hematol Oncol Stem Cell Ther. 2012;5(1):36-41.
Hamed, R. H., Anter, A. H., & Awad, I. A. (2012). A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective? Hematology/oncology and Stem Cell Therapy, 5(1), pp. 36-41. doi:10.5144/1658-3876.2012.36.
Hamed RH, Anter AH, Awad IA. A Randomized Trial of Brief Treatment of Early- Stage Hodgkin Lymphoma: Is It Effective. Hematol Oncol Stem Cell Ther. 2012;5(1):36-41. PubMed PMID: 22446609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective? AU - Hamed,R H, AU - Anter,A H, AU - Awad,I A, PY - 2012/3/27/entrez PY - 2012/3/27/pubmed PY - 2012/7/21/medline SP - 36 EP - 41 JF - Hematology/oncology and stem cell therapy JO - Hematol Oncol Stem Cell Ther VL - 5 IS - 1 N2 - BACKGROUND AND OBJECTIVES: Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin lymphoma with a favorable prognosis remains unclear. Therefore, we conducted this randomized trial, comparing two treatment groups consisting of a combination chemotherapy regimen of two different intensities followed by involved-field radiation therapy at two different dose levels. DESIGN AND SETTING: Prospective, randomized, in patients referred to the Department Of Clinical Oncology And Nuclear Medicine. PATIENTS AND METHODS: Ninety-eight patients with histologically proven early-stage Hodgkin lymphoma with a favorable prognosis were enrolled in this study between January 2008 and June 2010. They were randomly assigned in one of two treatment arms: arm I received four cycles of ABVD (adriamycin, belomycin, vinblastine, dacarbazine) followed by 30 Gy of involved-field radiation therapy; arm II received two cycles of ABVD followed by 20 Gy of involved-field radiation therapy. RESULTS: During the follow-up period, the 2-year relapse-free survival rates were 96% and 95% in arm I and arm II, respectively (P=.8), while the 2-year overall survival rates were 98% and 95% in arm I and arm II, respectively (P=.16). acute toxicity affected 54% of patients treated with four cycles of ABVD, who had grade III or IV toxicity, as compared with 30% of those receiving two cycles (P<.02). The rates of acute toxicity (grade III or IV) were also higher among patients treated with 30 Gy of involved-field radiation therapy than among those receiving 20 Gy (16% vs. 2.5%, P<.03) . CONCLUSION: In patients with early-stage Hodgkin lymphoma and a favorable prognosis, treatment with two cycles of aBVD followed by 20 Gy of involved-field radiation therapy was as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy. SN - 1658-3876 UR - https://www.unboundmedicine.com/medline/citation/22446609/A_randomized_trial_of_brief_treatment_of_early__stage_Hodgkin_lymphoma:_Is_it_effective L2 - https://linkinghub.elsevier.com/retrieve/pii/10.5144/1658-3876.2012.36 DB - PRIME DP - Unbound Medicine ER -